Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

181 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-11-21

Study Completion Date

2022-02-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the efficacy, safety and tolerability of various doses and durations of linezolid plus bedaquiline and pretomanid after 26 weeks of treatment in participants with either pulmonary XDR-TB, pre-XDR-TB, or treatment intolerant or non-responsive MDR-TB.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase 2 Trial Assessing TBAJ876 or Bedaquiline, with Pretomanid and Linezolid in Adults with Drug-sensitive Pulmonary Tuberculosis

NCT06058299

Pulmonary TB Pulmonary Tuberculosis Drug Sensitive Tuberculosis

ACTIVE_NOT_RECRUITING PHASE2

The Safety and Efficacy of BDL(Bedaquiline Plus Delamanid Plus Linezolid) Regimen in Subjects With Pulmonary Infection of Multi-drug Resistant Tuberculosis (MDR-TB) or Rifampicin-Resistant Tuberculosis (RR-TB)

NCT06476210

Pulmonary Tuberculosis

RECRUITING PHASE4

Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB

NCT06114628

Pulmonary Tuberculosis

RECRUITING PHASE2

Linezolid Instead of Ethambutol in Treatment of Drug-susceptible Tuberculosis

NCT01994460

Pulmonary Tuberculosis Without Resistance to Rifampicin

UNKNOWN PHASE2

Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort

NCT06081361

Pulmonary Tuberculosis Rifampicin-resistant Tuberculosis

ACTIVE_NOT_RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A phase 3, multi-center, partially-blinded, randomized clinical trial in 4 parallel treatment groups. Bedaquiline and pretomanid treatment will not be blinded. Linezolid treatment dose and duration will be double-blinded.

Participants will have a screening period of up to 14 days and will be randomized to receive one of the 4 active treatment arms. Participants will be randomized to one of the 4 regimens in a 1:1:1:1 ratio, using an interactive voice and web response system (IXRS) which will utilize a randomization system using stratification with a random element to allocate participants evenly across the arms by HIV status and type of TB.

Each participant will receive 26 weeks of treatment. If participant's week 16 sputum sample is culture positive between the week 16 and week 26 treatment visits and their clinical condition suggests they may have an ongoing TB infection, Investigator may consider extending current treatment to 39 weeks. If the culture results between week 16 and week 26 are contaminated, missing or considered an isolated positive without clinical significance, available culture results should be used to make this decision. All decisions regarding treatment extension should be discussed with and approved by, in consultation with the Sponsor Medical Monitor before implementation. The treatment may also require modification due to toxicities. All dose modifications should be discussed with the Sponsor Medical Monitor prior to implementation, unless a pause or dose reduction is required urgently for safety concerns.

Participants will be followed for 78 weeks after end of treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tuberculosis, Pulmonary Tuberculosis, Multidrug-Resistant Tuberculosis, MDR Tuberculosis Extensively Drug-Resistant Tuberculosis Pre-XDR-TB XDR-TB

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Participants, trial investigators and staff, including laboratory staff, will be blinded to dose and scheduled duration of linezolid. Bedaquiline and pretomanid dosing will not be blinded. There will be three unblinded analyses which will contain results by linezolid treatment group in aggregate. The first analysis will be after all participants have completed 26 weeks of treatment and here sites, participants, and Sponsor staff will not be unblinded to individual linezolid treatment information. A limited number of statisticians will have access to individual linezolid treatment assignments. The blind for all individual participants will be broken for the primary endpoint analysis (the second unblinded analysis) once all clinical data and outcome parameters have been captured, no more data queries are pending, and the statistical analysis plan has been finalized. The third analysis will occur when all participants have completed 78 weeks of follow-up after end of treatment.

Intervention Type DRUG

Scored 600 mg tablets

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female, aged 14 years or older.
* One of the following with documentation of culture positive or molecular test within 3 months of screening:

* XDR-TB defined as resistance to rifamycins, a fluoroquinolone AND an injectable OR
* Pre-XDR-TB with defined as resistance to rifamycins, and to a fluoroquinolone OR an injectable OR
* MDR-TB with resistance to rifamycins, and either non-responsive or non-tolerant to current treatment.
* Of non-childbearing potential or willing to practice effective birth control methods.
* Complete informed consent form.

Exclusion Criteria

* Karnofsky score \< 60 at screening.
* Body mass index (BMI) \< 17 kg/m2
* Participants who are expected to require a surgical procedure (for Pulmonary TB).
* Any risk factor for QT prolongation
* Pregnant or breast-feeding
* Any planned contraindicated medicines or received more than 2 weeks of bedaquiline, linezolid or delamanid prior to first dose of IMP.
* A peripheral neuropathy of Grade 3 or 4, according to DMID. Or, participants with a Grade 1 or 2 neuropathy which is likely to progress/worsen over the course of the study, in the opinion of the Investigator
* Any of the following lab toxicities/abnormalities:

* Viral load \>1000 copies/mL (Unless newly diagnosed HIV and not yet on ART who otherwise qualify for participation);
* CD4+ count \< 100 cells/µL (HIV positive participants);
* Serum potassium less than the lower limit of normal for the laboratory;
* Hemoglobin \< 9.0 g/dL or 90g/L;
* Platelets \<100,000/mm3 or \< 100 x 10\^9/L
* Absolute neutrophil count (ANC) \< 1500/ mm3 or \< 1.5 x 10\^9/L
* Aspartate aminotransferase (AST) and Alanini aminotransferase (ALT) Grade 3 or greater (\> 3.0 x ULN)
* Total bilirubin greater than 1.5 x ULN
* Direct bilirubin greater than ULN
* Serum creatinine level greater than 1.5 times upper limit of normal
* Albumin \<3.0 g/dl or \< 30 g/L

Minimum Eligible Age

14 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No